探索免疫蛋白质组以发现卵巢癌生物标志物。

Exploring the immunoproteome for ovarian cancer biomarker discovery.

作者信息

Martin Karina, Ricciardelli Carmela, Hoffmann Peter, Oehler Martin K

机构信息

Adelaide Proteomics Centre, School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia; E-Mails:

出版信息

Int J Mol Sci. 2011 Jan 14;12(1):410-28. doi: 10.3390/ijms12010410.

DOI:10.3390/ijms12010410

PMID:21339995

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3039961/

Abstract

Most scientific efforts towards early detection of ovarian cancer are commonly focused on the discovery of tumour-associated antigens (TAA). Autologous antibodies against TAA, however, may serve as more sensitive diagnostic markers. They circulate in the blood before TAA and are usually more abundant than the TAAs themselves as a result of amplification through the humoral immune response. Accumulating evidence also suggests that a humoral response already exists during malignant transformation when aberrant gene expression is translated into premalignant cellular changes. This article reviews the current knowledge about autoantibodies against TAA in ovarian cancer and presents current immunoproteomic approaches for their detection.

摘要

大多数针对卵巢癌早期检测的科研工作通常聚焦于肿瘤相关抗原（TAA）的发现。然而，针对TAA的自体抗体可能是更敏感的诊断标志物。它们在TAA之前就已在血液中循环，并且由于通过体液免疫反应的放大作用，其数量通常比TAA本身更为丰富。越来越多的证据还表明，当异常基因表达转化为癌前细胞变化时，体液反应在恶性转化过程中就已经存在。本文综述了目前关于卵巢癌中针对TAA的自身抗体的知识，并介绍了当前用于检测这些抗体的免疫蛋白质组学方法。